John Lechleiter - Eli Lilly Chairman, CEO and Pres
| LLY Stock | MXN 12,425 249.90 1.97% |
Chairman
Dr. John C. Lechleiter, Ph.D. is no longer Chairman of the Board of Eli Lilly And Co., effective May 31, 2017. He resigned as President, Chief Executive Officer effective December 31, 2016. A Ph.D. chemist by training, Dr. Lechleiter has over 37 years of experience with the company in a variety of roles of increasing responsibility in research and development, pharmaceutical operations, and corporate administration. As a result, he has a sound understanding of pharmaceutical research and development, sales and marketing, and manufacturing. since 2016.
| Age | 61 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 317 276 2000 |
| Web | https://www.lilly.com |
Eli Lilly Management Efficiency
The company has return on total asset (ROA) of 0.1148 % which means that it generated a profit of $0.1148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6464 %, meaning that it generated $0.6464 on every $100 dollars invested by stockholders. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | CHAIRMAN Age | ||
| Michael Lawrie | DXC Technology | 64 | |
| Simon Zaga | FibraHotel | N/A | |
| Rodney Sacks | Monster Beverage | 69 | |
| Hector Navarro | Grupo Sports World | ||
| Robert Switz | Micron Technology | 72 | |
| Robert McEwen | McEwen Mining | 73 | |
| Lowell McAdam | Verizon Communications | 62 | |
| Carlos Elizondo | Grupo Hotelero Santa | 54 | |
| Hilton Schlosberg | Monster Beverage | 70 | |
Management Performance
| Return On Equity | 0.65 | |||
| Return On Asset | 0.11 |
Eli Lilly Leadership Team
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ellen Marram, Lead Independent Director | ||
| Kathi Seifert, Independent Director | ||
| Ralph Alvarez, Independent Director | ||
| Jamere Jackson, Independent Director | ||
| Joshua Smiley, CFO, Senior Vice President | ||
| Fionnuala Walsh, Senior Vice President - Global Quality | ||
| Johna Norton, Senior Vice President - Global Quality | ||
| Juan Luciano, Director | ||
| Alonzo Weems, VP Officer | ||
| Alfonso Zulueta, Senior Vice President and President - Emerging Markets business | ||
| Anat Ashkenazi, VP CFO | ||
| Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health | ||
| John Lechleiter, Chairman, CEO and Pres | ||
| Anne White, Senior Vice President and Presidentident - Lilly Oncology | ||
| Karen Horn, Independent Director | ||
| Leigh Pusey, Senior Vice President - Corporate Affairs and Communications | ||
| Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer | ||
| Darren Carroll, Senior Vice President - Corporate Business Development | ||
| William Kaelin, Director | ||
| Karen Walker, Director | ||
| Jacob Naarden, CEO VP | ||
| Christi Shaw, Senior Vice President and President - Lilly Bio-Medicines | ||
| Barton Peterson, Senior Vice President - Corporate Affairs and Communications | ||
| Derica Rice, CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy Committee | ||
| Enrique Conterno, Sr. VP and President of Lilly Diabetes | ||
| Raul Alvarez, Independent Director | ||
| Marschall Runge, Director | ||
| Michael Harrington, General Counsel and Sr. VP | ||
| David Hoover, Independent Director | ||
| Maria Crowe, President - Manufacturing Operations | ||
| Anat JD, Gen VP | ||
| Myles ONeill, Senior Vice President and President - Manufacturing Operations | ||
| David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines | ||
| Daniel Skovronsky, Senior Vice President - Science and Technology, and President Lilly Research Laboratories | ||
| Diogo Rau, VP Officer | ||
| Donald Zakrowski, Chief Fin | ||
| Jan Lundberg, Executive VP of Science and Technology and President of Lilly Research Laboratories | ||
| Carolyn Bertozzi, Independent Director | ||
| Erik Fyrwald, Independent Director | ||
| Aarti Shah, Senior Vice President - Information Technology, and CIO | ||
| Susan Mahony, Senior Vice President and President - Lilly Oncology | ||
| Jackson Tai, Director | ||
| Michael Eskew, Independent Director | ||
| Martin MIBS, VP Projects | ||
| Katherine Baicker, Independent Director | ||
| Stephen Fry, Senior Vice President - Human Resources and Diversity | ||
| Franklyn Prendergast, Independent Director |
Eli Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.65 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 6.99 T | |||
| Shares Outstanding | 950.18 M | |||
| Shares Owned By Insiders | 0.15 % | |||
| Shares Owned By Institutions | 85.00 % | |||
| Price To Earning | 333.06 X | |||
| Price To Book | 34.76 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |